Some issues in screening for breast and other cancers

Journal of Medical Screening

Volumn 13, Issue SUPPL.1, 2006, Pages

  Duffy, Stephen W ^a   McCann, Jenny ^b   Godward, Sara ^b   Gabe, Rhian ^c   Warwick, Jane ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b East Anglia Cancer Intelligence Unit   (United Kingdom)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; HUMAN; MAMMOGRAPHY; MASS SCREENING; METHODOLOGY; NEOPLASM; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

BREAST NEOPLASMS; FEMALE; HUMANS; MAMMOGRAPHY; MASS SCREENING; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 34247208079     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. IARC Working Group on the Evaluation of Cancer-Preventive Strategies. Breast Cancer Screening. Lyon: IARC Press, 2002
2. Scholefield JH, Moss S, Sufi F, Mangham CM, Hardcastle JD. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut 2002;50:840-4 (Pubitemid 34539047)
3. Anttila A, Ronco G, Clifford G, et al. Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer 2004;91:935-41 (Pubitemid 39273788)
4. Tabar L, Vitak B, Chen HH, et al. The Swedish Two-County Trial twenty years later - updated mortality results and new insights from long-term follow-up. Radiol Clin North Am 2000;38:625-51 (Pubitemid 30640056)
5. Tabar L, Yen MF, Vitak B, Chen HHT, Smith RA, Duffy SW. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 2003;361:1405-10 (Pubitemid 36515039)
6. Otto SJ, Fracheboud J, Looman CWN, et al. Initiation of population-based mammography screening in Dutch municipalities and effect on breastcancer mortality: a systematic review. Lancet 2003;361:1411-17 (Pubitemid 36515040)
7. Fielder HM, Warwick J, Brook D, et al. A case-control study to estimate the impact on breast cancer death of the breast screening programme in Wales. J Med Screen 2004;11: 194-8 (Pubitemid 40006743)
8. Tabar L, Fagerberg G, Chen HH, Duffy SW, Gad A. Tumour development, histology and grade of breast cancers: prognosis and progression. Int J Cancer 1996;66:413-19 (Pubitemid 26176764)
9. Alexander FE, Anderson TJ, Hubbard AL. Screening status in relation to biological and chronological characteristics of breast cancers: a cross sectional survey. J Med Screen 1997;4:152-7 (Pubitemid 28270256)
10. Tabar L, Chen HH, Yen MF, et al. Mammographic tumour features can predict long-term outcomes reliably in women with 1-14-mm invasive breast carcinoma. Cancer 2004;101:1745-59
11. Yankaskas BC, Klabunde CN, Ancelle-Park R, et al. International comparison of performance measures for screening mammography can it be done?. 2004;11:187-93
12. Tabar L, Vitak B, Yen MFA, Chen HHT, Smith RA, Duffy SW. Number needed to screen lives saved over 20 years of follow-up in mammographic screening. J Med Screen 2004;11:126-9 (Pubitemid 39274093)
13. Paci E, Warwick J, Falini P, Duffy SW. Overdiagnosis in screening: is the increase in breast cancer incidence rates a cause for concern? J Med Screen 2004;11:23-7 (Pubitemid 38365691)
14. Yen MF, Tabar L, Vitak B, Smith RA, Chen HH, Duffy SW. Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer 2003;39:1746-54 (Pubitemid 36897612)
15. Bashir S, Esteve J. Analysing the difference due to risk and demographic factors for incidence or mortality. Int J Epidemiol 2000;29:878-84
16. Duffy SW, Tabar L, Vitak B, et al. The relative contributions of screendetected in situ and invasive breast carcinomas in reducing mortality from the disease. Eur J Cancer 2003;39:1755-60 (Pubitemid 36897613)
17. Tabar L, Chen HH, Fagerberg G, Duffy SW, Smith TC. Recent results from the Swedish two-county trial: the effects of age, histologic type, and mode of detection on the efficacy of breast cancer screening. J Natl Cancer Inst Monogr 1997;22:43-8
18. Tabar L, Larsson LG, Anderson I, et al. Breast-cancer screening with mammography in women aged 40-49 years. Int J Cancer 1996;68:693-9 (Pubitemid 27062026)
19. Smith RA, Duffy SW, Tabar L, Gabe RL. Screening and Early Detection. In: Singletary SE, Robb GL, Hortobagyi GN, eds. Advanced Therapy of Breast Disease. London: BC Decker Inc, 2004;202-12
20. Jorgensen OD, Kronberg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 2002;50:29-32 (Pubitemid 34028299)
21. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000;343:1603-7 (Pubitemid 32162983)
22. Atkin WS, Edwards R, Wardle J, et al. Design of a multicentre randomised trial to evaluate flexible sigmoidoscopy in colorectal cancer screening. J Med Screen 2001;8:137-44 (Pubitemid 32929839)
23. Barkun AN, Jobin G, Cousineau G, et al. The Quebec Association of Gastroenterology position paper on colorectal cancer screening - 2003. J Med Screen 2004;18:509-19 (Pubitemid 39248252)
24. Hernandez J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 2004;101:894-904 (Pubitemid 39100420)
25. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003;362:1871-6 (Pubitemid 37518501)
26. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004;3:355-66 (Pubitemid 38702089)
27. Henschke CI, Naidich DP, Yankelevitz DF, et al. Early lung cancer action project - initial findings on repeat screening. Cancer 2001;92:153-9 (Pubitemid 32623052)
28. Gohagan J, Marcus P, Fagerstrom R, Pinsky P, Kramer B, Prorok P. Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph - The Lung Screening Study of the National Cancer Institute. Chest 2004;126:114-21 (Pubitemid 38943126)
29. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130: 417-22
30. Chen JG, Parkin DM, Chen QG, et al. Screening for liver cancer: results of a randomized controlled trial in Qidong, China. J Med Screen 2003;10:204-9 (Pubitemid 38091209)
31. Chen THH, Chen CJ, Yen MF, et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer 2002;98:257-61
32. Chen HH, Prevost TC, Duffy SW. Evaluation of screening for nasopharyngeal carcinoma: trial design using Markov chain models. Br J Cancer 1999;79:1894-900 (Pubitemid 29132321)
33. Zong YS, Sham JST, Ng MH, et al. Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer 1992;69:3-7
34. Ramadas K, Sankaranarayanan R, Jacob BJ, et al. Interim results from a cluster randomized controlled oral cancer screening trial in Kerala, India. Oral Oncol 2003;39:580-8 (Pubitemid 36694482)
35. Dinis-Ribeiro M, Yamaki G, Miki K, Costa-Pereira A, Matsukawa M, Kurihara M. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen 2004;11:141-7 (Pubitemid 39274096)